Mississauga, ON -- (SBWire) -- 03/20/2018 --AllPennyStocks.com Media, Inc. (http://www.AllPennyStocks.com/) announces its latest article titled "Antibe Therapeutics' Stock Surges on Successful Phase 2B Gastrointestinal Safety Study for Lead Pain Drug, ATB-346."
Companies mentioned in this article include Antibe Therapeutics Inc. (TSX-Venture:ATE) (OTCQB:ATBPF).
Article Excerpt:
Once shares of Antibe Therapeutics Inc. (TSX-Venture:ATE) (OTCQB:ATBPF) had their trading halt lifted, the company announced that its lead drug, ATB-346, met its primary endpoint in the Phase 2B gastrointestinal ("GI") safety study. The double-blind study was conducted in 244 healthy volunteers and was designed to demonstrate the superiority of ATB-346 in GI safety compared to naproxen, the most prescribed nonsteroidal anti-inflammatory drug ("NSAID") in the USA. Subjects on ATB-346 exhibited an ulceration rate of 2.5% versus an ulceration rate of 42.1% for subjects on naproxen at the end of the 2-week treatment period, with a very high degree of statistical significance (p<0.001). ATB-346 was also safe and well tolerated.
As a result of the positive results, shares shot up 78% in early-afternoon trading on very high volume as shareholders cheered on the impressive data. Antibe's Chief Scientific Officer, John Wallace, commented, "The successful outcome of this study is the culmination of 15+ years of scientific research, and validates Antibe's hydrogen sulfide-releasing technology. Gastrointestinal safety has been a major global concern with NSAIDs for decades and we now have clinical data unequivocally demonstrating a solution to this unmet and serious medical problem."
The full version of this article can be found at:
http://www.allpennystocks.com/aps_ca/special-reports/873/antibe-therapeutics-stock-surges-on-successful-phase-2b-gastrointestinal-safety-study-for-lead-pain-drug-atb-346.htm
About AllPennyStocks.com
AllPennyStocks.com is focused on the small-cap / penny stock market and has become a reputable name in the investment community. AllPennyStocks.com runs a Canadian and US site to provide investors in Canada as well as the United States with informative and unique content and information. AllPennyStocks.com runs daily technical penny stocks to watch, has a daily market write-up, provides company spotlights, runs unique most active pages strictly for penny stocks trading on the TSX, TSX Venture, NASDAQ and OTC BB, and much more information for the average investor.
AllPennyStocks.com also runs an email newsletter that aims to uncover stocks that are still under the radar of most investors. Criteria AllPennyStocks.com looks for includes strong revenues, a seasoned management, innovative business plans, among many others. AllPennyStocks.com also looks for companies that announce breaking news, recent 52-week highs/lows, technical breakouts, and other favorable corporate information.
Investors are encouraged to subscribe to the AllPennyStocks.com FREE e-mail newsletter and see what tens of thousands of other investors have already been receiving since 1999. Investors can receive their free newsletter subscription by clicking here: http://www.allpennystocks.com/aps_common/newsletter_free.asp.
Contact:
AllPennyStocks.com Media, Inc.
Peter Szafranski -- President
Phone: 905-361-5680
E-Mail: peter@allpennystocks.com
Websites: http://www.allpennystocks.com / http://www.bullishinvestor.com
Note: AllPennyStocks.com has not received compensation for carrying the above-mentioned company; a full disclaimer can be viewed here: http://www.allpennystocks.com/aps_common/disclaimer.asp.
AllPennyStocks.com News: Antibe Therapeutics' Stock Surges on Successful Phase 2B Gastrointestinal Safety Study for Lead Pain Drug, ATB-346